Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem cell disorder characterized by chronic hemolysis and potentially life-threatening thrombotic episodes. Advances in research have led to the approval and ongoing development of complement inhibitors that significantly reduce PNH-associated morbidities. Recent innovations include novel and emerging proximal complement inhibitors, which may further improve PNH care by decreasing patients’ residual anemia and transfusion dependence. In this video, leading experts discuss the latest clinical evidence and practical applications of proximal complement inhibitors in PNH, offering strategies to optimize treatment plans, monitor patient response, and manage adverse events.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/extra-measures-extra-challenges-paroxysmal-nocturnal-hemoglobinuria-latest
- Start Date: 2024-10-25 05:00:00
- End Date: 2024-10-25 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Novartis Corporation Pharmaceuticals - Amount: 62750.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest